Long-term cardiovascular risk in transplantation insights from the use of everolimus in heart transplantation
|
|
- Victoria Roberts
- 6 years ago
- Views:
Transcription
1 Nephrol Dial Transplant (2006) 21 [Suppl 3]: iii9 iii13 doi: /ndt/gfl295 Long-term cardiovascular risk in transplantation insights from the use of everolimus in heart transplantation Howard Eisen Cardiology Division, Drexel University College of Medicine, Philadelphia, PA, USA Abstract Everolimus is a potent immunosuppressive agent that has anti-proliferative activity. The benefits of everolimus vs azathioprine in de novo heart transplant recipients were assessed in a randomized, double-blind study. Patients (n ¼ 634) were randomized to receive everolimus (1.5 mg/day or 3.0 mg/day) or azathioprine; all patients received steroids and full-dose ciclosporin (CsA). The primary endpoint was the incidence of efficacy failure [biopsy-proven acute rejection (BPAR), graft loss, death or loss to follow-up]. The incidence of cardiac allograft vasculopathy (CAV) was assessed by intravascular ultrasound. The incidence and hospitalization costs of major adverse cardiac events (MACE) were assessed after 4 years. The incidence of efficacy failure was significantly reduced with everolimus compared with azathioprine at 12, 24 and 48 months (P < 0.05), largely because of a lower incidence of BPAR. An increase in serum creatinine levels was seen with everolimus compared with azathioprine, likely attributed to CsA nephrotoxicity. There was a significantly larger increase in vascular intimal thickness with azathioprine than with everolimus (P 0.01), which was accompanied by a significantly lower incidence of CAV in the everolimus groups. After 4 years, the incidence of MACE was higher with azathioprine than with either dose of everolimus. MACE-related treatment costs were estimated at $ for azathioprine, $ for everolimus 1.5 mg/day (68% saving) and $ for everolimus 3.0 mg/day (56% saving). Everolimus is significantly more effective than azathioprine in preventing efficacy failure in de novo heart transplant recipients and is also associated with reduced incidence and severity of CAV and MACE at 4 years post-transplant. The reduced 4-year Correspondence and offprint requests to: Howard Eisen, Cardiology Division, Drexel University College of Medicine, 245 N. 15th Street MS #1012, Philadelphia, PA 19102, USA. heisen@drexelmed.edu incidence of MACE is likely to lead to substantially reduced hospitalization costs. Since cardiovascular morbidity and mortality are important factors in the long-term survival of renal transplant recipients, applying lessons from the use of everolimus in heart transplantation may further improve the understanding of managing cardiovascular risk in renal transplantation. Keywords: azathioprine; cardiac allograft vasculopathy; everolimus; heart transplantation; MACE; renal transplantation Introduction Everolimus (Certican Õ, Novartis Pharma AG, Basel, Switzerland) is a potent immunosuppressant that also has important anti-proliferative properties; both of these effects are related to its action as a proliferation signal inhibitor. Growth factors, such as interleukin 2, that are secreted by T-cells are important in promoting clonal lymphocyte expansion. While calcineurin inhibitors (CNIs) prevent the production of such growth factors, everolimus acts further downstream to prevent antigen-driven T-cell proliferation [1]. Everolimus also differs from mycophenolic acid-based agents, which inhibit the de novo pathway of purine synthesis. Importantly, the anti-proliferative actions of everolimus are not limited to the immune system, but also act to reduce vascular smooth muscle proliferation [2] and prevent vascular remodelling [3], which is known to be a key component of progressive allograft dysfunction [4]. The use of everolimus in de novo heart transplant recipients has significant benefits in reducing the incidence of cardiac allograft vasculopathy (CAV) [5 7] and associated major adverse cardiac events (MACE) [8]. Given that cardiovascular morbidity and mortality have a major impact on the longterm survival of renal transplant recipients, the implications of these studies may be relevant in renal transplantation. ß The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 iii10 Efficacy of everolimus in de novo heart transplant recipients The everolimus B253 study was a randomized, doubleblind trial comparing everolimus (1.5 mg/day or 3.0 mg/day) with azathioprine (1 3 mg/kg/day) in 634 de novo heart transplant recipients [5 7]. The primary objective of the study was to assess the efficacy of everolimus in terms of a composite efficacy failure endpoint consisting of the incidence of biopsy-proven acute rejection (BPAR) of at least grade 3A (or any rejection associated with haemodynamic compromise), graft loss, death or loss to follow-up. Secondary endpoints included the individual components of the composite endpoint, as well as the incidence of CAV, assessed by intravascular ultrasound (IVUS). Safety assessments included adverse events, infections and laboratory parameters. Patients were randomized to treatment within 72 h after transplantation, and all the patients received full-dose ciclosporin (CsA) microemulsion (maintaining trough blood levels of ng/ml) and steroids ( mg/kg/day) in addition to the study medication. The initial study period was 2 years, and this was followed by a 4 year extension [7]. After 12 months of treatment, the incidence of efficacy failure was significantly reduced with both doses of everolimus compared with azathioprine (P < 0.05; Figure 1) [5]. Subsequent follow-up has shown that the superior efficacy of everolimus was maintained at 24 and 48 months (Figure 1) [6,7]. Analysis of secondary endpoints revealed that the increased incidence of efficacy failure in the azathioprine group was largely the result of an increased incidence of BPAR. At 24 months, the incidence of BPAR in the azathioprine group was 48.1% compared with 34.9% and 22.7% in the everolimus 1.5 mg/day and 3.0 mg/day groups, respectively (P < 0.05) [6]. Over the first 12 months of treatment, everolimus was associated with an increase in serum creatinine levels compared with azathioprine, which is likely to be related to potentiation of the nephrotoxic effects of CsA [5]. A significant difference between the azathioprine and everolimus groups with regard to serum creatinine continued to be evident up to 48 months [7], although the creatinine level stabilized after month 12 as the result of a protocol amendment stating that CsA trough blood levels should be maintained at a lower level of 100 ng/ml, while everolimus trough blood levels remain within the recommended target level (i.e. more than 3 ng/ml) [5,6]. In light of these observations, the CsA dose should be reduced early post-transplant; this approach has been proven to maintain immunosuppressive efficacy in clinical experience [9 11]. Assessment of cardiac allograft vasculopathy by intravascular ultrasound The main component of post-transplant vasculopathy is intimal thickening as a result of smooth muscle H. Eisen Fig. 1. Percentage of patients experiencing treatment failure during treatment with azathioprine or everolimus [5 7]. cell proliferation [12], and thus the condition can be considered as a proliferative disease. IVUS is an important technique for the assessment of CAV, as it is the only available technique that allows simultaneous assessment of lumen size and vessel wall morphology. This provides an important advantage over coronary angiography, which simply outlines the vessel lumen with contrast dye. Thus, a vessel which appears normal on a coronary angiogram may reveal significant amounts of atherosclerosis or intimal thickening using IVUS [13]. Moreover, an IVUS validation study in 125 primary heart transplant recipients suggested that the incidence of CAV (defined as progression of intimal thickening by more than 0.5 mm) in the first year after transplantation is a reliable surrogate marker for subsequent mortality and non-fatal MACE within 5 years after heart transplantation [14]. In the everolimus B253 study, CAV was assessed by IVUS in a subgroup of patients, with the first assessment carried out at baseline (i.e. during the first weeks after transplantation), and follow-up evaluations after 1 and 2 years post-transplantation. After 1 year of treatment, the average increase in intimal thickness was significantly larger (0.10 mm) with azathioprine than with everolimus 1.5 mg/day (0.04 mm; P ¼ 0.01) or 3.0 mg/day (0.03 mm; P ¼ 0.003) [5]. This was accompanied by a significantly lower incidence of CAV in the everolimus 1.5 mg/day (35.7%; P ¼ 0.045) and 3.0 mg/day (30.4%; P ¼ 0.01) groups compared with the azathioprine group (52.8%). Results from the 24 month analysis show that these benefits on IVUS parameters and incidence of CAV are maintained (Table 1) [6].
3 Insights from use of everolimus in heart transplantation Table 1. Parameters of allograft vasculopathy assessed by intravascular ultrasound (IVUS) after 24 months of treatment with everolimus or azathioprine (6, Novartis data on file) iii11 IVUS measurement: change from baseline Everolimus 1.5 mg/day (n ¼ 45/209) Everolimus 3.0 mg/day (n ¼ 44/211) Azathioprine (n ¼ 60/214) Maximum intimal thickness (mm) 0.07* 0.06** 0.15 Intimal area (mm 2 ) 0.79** 0.83** 1.52 Intimal volume (mm 3 ) ** Incidence of vasculopathy (%) 33.3* *P < 0.05 vs azathioprine; **P < 0.01 vs azathioprine. Major adverse cardiac events in heart transplant recipients Patients who had an IVUS measurement at baseline and at 1 year in the B253 study were eligible for a 4 year evaluation of MACE [defined as acute myocardial infarction, congestive heart failure, percutaneous cardiac intervention (PCI), coronary artery bypass grafting (CABG), implantable cardiac defibrillator (ICD), cerebrovascular accident or peripheral vascular disease] [8]. This evaluation included 211 patients (azathioprine, n ¼ 72; everolimus 1.5 mg/day, n ¼ 70; everolimus 3.0 mg/day, n ¼ 69), with all the incidences of MACE occurring after the first month of treatment included in the analysis. Similarly to the incidence of CAV, at 4 years posttransplant, the total incidence of MACE was higher with azathioprine than with either dose of everolimus (Figure 2) [8]. The majority of occurrences of MACE comprised congestive heart failure, with no incidences of CABG or ICD reported in the 4 years of follow-up. Notably, the reduced incidence of MACE in the everolimus groups was largely accounted for by a reduced incidence of PCI (mainly angioplasty), with six incidences of PCI in the azathioprine group compared with one in the everolimus 3.0 mg/day group. There were no incidences of PCI in the everolimus 1.5 mg/day group. Two deaths, as a result of MACE were reported during the study, both of which occurred in azathioprine-treated patients with CAV. One patient died as a result of coronary heart failure and one due to coronary artery occlusion. To calculate the treatment costs of MACE, data for the mean costs of hospitalization were obtained from the US Healthcare Cost and Utilization Project, in which costs ranged from $ for a CABG to $ for congestive heart failure [15]. Overall, the total treatment costs for MACE were estimated at $ for azathioprine, $ for everolimus 1.5 mg/day and $ for everolimus 3.0 mg/day (Table 2), representing economic savings of 68.3% for everolimus 1.5 mg/day and 55.5% for everolimus 3.0 mg/day vs azathioprine [8]. Discussion The results of the B253 study have a number of important implications for renal transplant recipients. Fig. 2. Incidence of major adverse cardiac events (MACE) within 4 years after transplant in patients receiving azathioprine or everolimus [8]. Patients who receive a renal transplant are at a significantly increased risk of cardiovascular disease [16 18]. This is, in turn, is associated with a substantially increased risk of cardiovascular mortality [18]. Therefore, it is critical that immunosuppressive regimens are chosen that combine optimum efficacy with minimal risk of cardiovascular disease. The results of the B253 study show that the use of everolimus in heart transplant recipients can significantly reduce the incidence of cardiovascular disease compared with azathioprine, with the potential to reduce healthcare costs, and it seems likely that similar results will be seen in renal transplant recipients. Indeed, reports of everolimus use in renal transplant recipients suggest that it may be beneficial for cardiovascular risk factors such as hypertension (see case report by Pascual in this supplement). In clinical studies, everolimus has been associated with an increased risk of dyslipidaemia [19], although this can easily be managed with statin therapy [20]. Notably, when combined with reduceddose CsA therapy, everolimus 1.5 mg/day is associated with a lower incidence of hypertension, hypercholesterolaemia and hypertriglyceridaemia compared with either everolimus plus full-dose CsA or mycophenolate mofetil (MMF) plus full-dose CsA [21]. Results from the B253 study also confirm the effects of concomitant administration of everolimus
4 iii12 H. Eisen Table 2. Estimated hospitalization costs of major adverse cardiac events (MACE) in patients receiving everolimus or azathioprine for 4 years [8] Everolimus 1.5 mg/day Everolimus 3.0 mg/day Azathioprine MACE 1 CHF ¼ $ PCI ¼ $ CVA ¼ $ AMI¼ $ PVD ¼ $ Total MACE Total hospitalization cost $ $ $ Everolimus vs azathioprine 68.30% 55.50% AMI, acute myocardial infarction; CHF, congestive heart failure; CVA, cerebrovascular accident; MACE, major cardiac adverse events; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease. plus full-dose CsA on renal function, with significantly higher serum creatinine levels reported in the everolimus groups compared with the azathioprine group after 12 months of treatment [5]. Studies in renal transplant recipients have shown similar results for everolimus and full-dose CsA in comparison with MMF [22,23]. however, this effect is unlikely to be the result of a direct effect of everolimus to induce renal dysfunction, and is instead related to the potentiation of CsA-related nephrotoxicity. Thus, in the B253 study, a reduction in trough blood levels of CsA led to the stabilization of serum creatinine [5,7]. Clinical experience with everolimus and low-dose CNI in heart transplantation also suggests that this is an efficacious regimen leading to preservation of renal function [24]. Furthermore, it has also been shown that de novo renal transplant recipients who receive everolimus plus a reduced exposure to CsA achieve comparable efficacy with those receiving full-dose CsA, with improved renal function [25,26]. Use of everolimus has been found to enable a 57% reduction in the dose of CsA; this was associated with improvements in serum creatinine levels and creatinine clearance over 6 and 12 months [21,25]. Conclusions Heart transplant recipients receiving everolimus in combination with CsA and steroids experience a significantly lower incidence of treatment failure 4 years post-transplant compared with azathioprine, largely as a result of a reduced risk of BPAR. Importantly, despite increased lipid levels in patients receiving everolimus, there are substantial cardiovascular benefits in these patients, including significant reductions in the incidence and severity of CAV, and a reduced incidence of MACE at 4 years after transplantation. Renal transplant recipients may experience similar benefits on cardiovascular disease, as these patients are known to be at a high risk of cardiovascular morbidity and mortality. Optimization of CsA levels is required to provide the maximum level of graft protection and tolerability. Acknowledgement. Editorial assistance was provided by Ogilvy 4D. Conflict of interest statement. The author received an honorarium from Novartis Pharma AG for speaking at a meeting in Geneva, October 2005, on the role of everolimus in cardiovascular risk management in renal transplantation. References 1. Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative. Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995; 59: Schuurman H-J, Pally C, Weckbecker G, Schuler W, Bruns C. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999; 31: Neumayer H-H. Introducing everolimus (Certican Õ ) in organ transplantation: an overview of preclinical and early clinical developments. Transplantation 2005; 79: S72 S75 5. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiactransplant recipients. N Engl J Med 2003; 349: Mancini D, Vigano` M, Pulpon LA et al. 24-month results of a multicenter study of everolimus for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients. Poster presented at the American Transplant Congress, Washington, DC, USA: Kobashigawa J, Hare J, Eisen H et al. Everolimus in cardiac transplantation: 48 month results. Presented at the American Transplant Congress, Seattle, WA, USA: Eisen H, Starling RC, Kobashigawa J. Incidence of MACE and economic burden in de novo heart transplant patients: a 4-year comparison of everolimus and azathioprine. Transplant Int 2005; 18: PO Lehmkuhl H, Dandel M, Hiemann N et al. 1-year single center clinical experience with everolimus (Certican Õ )inde novo heart transplant recipients. Submitted to Transplantation Lehmkuhl H, Hetzer R. Clinical experience with Certican Õ (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin. J Heart Lung Transplant 2005; 24 [Suppl 4]: S201 S205
5 Insights from use of everolimus in heart transplantation 11. Zuckermann A. Clinical experience with Certican Õ (everolimus) in maintenance heart transplant patients at the Medical University of Vienna. J Heart Lung Transplant 2005; 24 [Suppl 4]: S206 S Aranda JM,Jr, Hill J. Cardiac transplant vasculopathy. Chest 2000; 118: Kapadia SR, Nissen SE, Tuzcu EM. Impact of intravascular ultrasound in understanding transplant coronary artery disease. Curr Opin Cardiol 1999; 14: Kobashigawa JA, Tobis JM, Starling RC et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005; 45: HCUPnet. Healthcare Cost and Utilization Project. hcup.ahrq.gov/ Massy ZA. Hyperlipidemia and cardiovascular disease after organ transplantation. Transplantation 2001; 72: S13 S Marce n R, Morales JM, Ferna ndez-juárez G et al. Risk factors of ischemic heart disease after renal transplantation. Transplant Proc 2002; 34: Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112 S Pascual J, Boletis I, Campistol JM. Everolimus (Certican Õ ) in renal transplantation: a review of clinical trial data, current usage and future directions. Transplantation Rev 2006; 20: 1 18 iii Pascual J, Marce n R, Ortun o J. Clinical experience with everolimus (Certican Õ ): optimizing dose and tolerability. Transplantation 2005; 79: S80 S Pascual J. Concentration-controlled everolimus (Certican Õ ): combination with reduced dose calcineurin inhibitors. Transplantation 2005; 79: S76 S Vı tko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: Lorber MI, Mulgaonkar S, Butt KMH et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: Lehmkuhl H, Ross H, Eisen H, Valantine H. Everolimus (Certican Õ ) in heart transplantation optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 2005; 37: Vitko S, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipient: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78:
Emerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationClinical decisions regarding immunosuppressive
PHARMACOLOGIC THERAPIES AND RATIONALES * Stuart D. Russell, MD ABSTRACT This article reviews evidence related to the use of induction therapy and longer-term combination immunosuppressive drug regimens
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationHeart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
More informationPleiotropic effects of mtor inhibitors : cardiovascular and cancer. Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble
Pleiotropic effects of mtor inhibitors : cardiovascular and cancer Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble Tehran August 2016 Why this topic? Since last year very little news in the immunosuppressive
More informationPCI in Patients with Transplant Coronary Artery Disease. Michael S. Lee, MD, FACC, FSCAI Assistant Professor UCLA School of Medicine
PCI in Patients with Transplant Coronary Artery Disease Michael S. Lee, MD, FACC, FSCAI Assistant Professor UCLA School of Medicine Faculty Disclosure Honararia for Boston Scientific, BMS, Daiichi Sankyo,
More informationJACC: Heart Failure Vol. 1, No. 5, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN /$36.00
Ó 2013 by the American College of Cardiology Foundation ISSN 2213-1779/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jchf.2013.07.002 Cardiac Allograft Vasculopathy by Intravascular Ultrasound
More informationrecipients: What does the evidence tell us now? The efficacy of everolimus with reduced cyclosporine in de novo heart
Seite 1 von 40 Everolimus immunosuppression in de novo heart transplant recipients: What does the evidence tell us now? Abstract The efficacy of everolimus with reduced cyclosporine in de novo heart transplant
More informationScottish Medicines Consortium
Scottish Medicines Consortium tacrolimus, 5mg/ml concentrate for infusion and 0.5mg, 1mg, 5mg hard capsules (Prograf ) No. (346/07) Astellas Pharma Ltd 12 January 2007 The Scottish Medicines Consortium
More informationCombination of a Calcineurin Inhibitor and a Mammalian Target of Rapamycin Inhibitor: Not So Nephrotoxic As We Thought?
Trends in Transplant. 2011;5:49-56Helio Tedesco Silva Junior: Calcineurin and mtor inhibitor nephrotoxicity Combination of a Calcineurin Inhibitor and a Mammalian Target of Rapamycin Inhibitor: Not So
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationIMMUNOSUPPRESSION. Background:
IMMUNOSUPPRESSION Tacrolimus Versus Cyclosporine Microemulsion for Heart Transplant Recipients: A Meta-analysis Fan Ye, MD, a Xiao Ying-Bin, MD, a Weng Yu-Guo, MD, b and Roland Hetzer, MD b Background:
More informationCardiac allograft vasculopathy (CAV) is a
CARDIAC ALLOGRAFT VASCULOPATHY: BACKGROUND AND RECENT ADVANCES * Jon A. Kobashigawa, MD ABSTRACT Coronary artery disease in the transplanted heart, also known as cardiac allograft vasculopathy (CAV), is
More informationRenal transplant dysfunction importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality
Nephrol Dial Transplant (2006) 21: 2282 2289 doi:10.1093/ndt/gfl095 Advance Access publication 30 March 2006 Original Article Renal transplant dysfunction importance quantified in comparison with traditional
More informationPremier Health Plan considers Intravascular Ultrasound (IVUS) for Coronary Vessels medically necessary for the following indications:
Premier Health Plan POLICY AND PROCEDURE MANUAL MP.091.PH - Intravascular Ultrasound for Coronary Vessels This policy applies to the following lines of business: Premier Commercial Premier Employee Premier
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for
More informationHeart Rate and Cardiac Allograft Vasculopathy in Heart Transplant Recipients
ESC Congress 2011 Paris 27-31 August Heart Rate and Cardiac Allograft Vasculopathy in Heart Transplant Recipients M.T. La Rovere, F. Olmetti, G.D. Pinna, R. Maestri, D. Lilleri, A. D Armini, M. Viganò,
More informationKidneytransplant pathologyrelatedto immunosuppressiveagents
Kidneytransplant pathologyrelatedto immunosuppressiveagents Helmut Hopfer Pathologie Women, 53 years old. 16 months after kidney transplantation for diabetic nephropathy. Metabolicsyndromeandcoronaryheartdisease.
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationCase Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
Case Reports in Transplantation, Article ID 190516, 4 pages http://dx.doi.org/10.1155/2014/190516 Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationCyclosporine (CsA) dose adjustments based on. C 2 Monitoring of Cyclosporine in De Novo Liver Transplant Recipients: The Clinician s Perspective
REVIEW C 2 Monitoring of Cyclosporine in De Novo Liver Transplant Recipients: The Clinician s Perspective Federico Villamil 1 and Stephen Pollard 2 Adjusting cyclosporine (CsA) dose based on blood concentration
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationEarly Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation
Trends in Transplantation Transplant. 2012;6:28-33 Early Conversion from a Calcineurin Inhibitor-Based Regimen to Everolimus-Based Immunosuppression after Kidney Transplantation Hallvard Holdaas Department
More informationReduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival
Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function
More informationRetransplant and Medical Therapy for Cardiac Allograft Vasculopathy: International Society for Heart and Lung Transplantation Registry Analysis
American Journal of Transplantation 2016; 16: 301 309 Wiley Periodicals Inc. Brief Communication C Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationCulprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationReview Article Everolimus in Heart Transplantation: An Update
Journal of Transplantation Volume 2013, Article ID 683964, 12pages http://dx.doi.org/10.1155/2013/683964 Review Article Everolimus in Heart Transplantation: An Update Stephan W. Hirt, 1 Christoph Bara,
More informationPost Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ
Post Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ Art of Good Cooking Good Ingredient Good donor + OK recipient Good technique Good team Good timing Good
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationChapter 9: Cardiovascular Disease in Patients With ESRD
Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in adult ESRD patients, with atherosclerotic heart disease and congestive heart failure being the most common conditions
More informationProteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation
Trends Fritz in Transplant. Diekmann: 2011;5:139-43 Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation
More informationIntravascular Ultrasound
May 2008 Beth Israel Deaconess Medical Center Harvard Medical School Intravascular Ultrasound Matthew Altman, HMS III Gillian Lieberman, MD BIDMC Department of Radiology Presentation Overview 1. Patient
More informationGeneral Introduction. 1 general introduction 13
General Introduction In The Netherlands 13,000 patients suffer from end stage renal disease (ESRD), which left untreated inevitably results in death. Every year this number increases with approximately
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationDeclaration of conflict of interest. Nothing to disclose
Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. Management of Renal Dysfunction in Extra Renal Transplants
2017 CST-Astellas Canadian Transplant Fellows Symposium Management of Renal Dysfunction in Extra Renal Transplants Jeffrey Schiff, MD Dr. Jeffrey Schiff is an Assistant Professor of Medicine at the University
More informationSirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 4, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/10/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.02.005 CLINICAL
More informationAmerican Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.
American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in ESRD patients, with atherosclerotic heart disease and congestive heart
More informationDate: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationSince TAC was introduced into the clinic in 1989 (1Y5), it
CLINICAL AND TRANSLATIONAL RESEARCH Ten-Year Results of a Randomized Trial Comparing Tacrolimus Versus Cyclosporine A in Combination With Mycophenolate Mofetil After Heart Transplantation Sonja Guethoff,
More informationLiver Transplant Immunosuppression
Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationTrends in Transplant. 2013;7:3-10 Tainá Veras de Sandes-Freitas, et al.: Cytomegalovirus Infection and Everolimus
Trends in Transplant. 2013;7:3-10 Tainá Veras de Sandes-Freitas, et al.: Cytomegalovirus Infection and Everolimus Cytomegalovirus Infections in Everolimus-Based Treatment Tainá Veras de Sandes-Freitas,
More informationWhy Do We Need New Immunosuppressive Agents
Why Do We Need New Immunosuppressive Agents 1 Reducing acute rejection rates has not transplanted into better long-term graft survival Incidence of early acute rejection episodes by era Relative risk for
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationPost Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.
Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for
More informationLothar Bernd Zimmerhackl
What works in current paediatric practice of off-label dose adjustment of adult doses? Lothar Bernd Zimmerhackl Medical University Innsbruck Austria AGAH Workshop: Pediatric Investigation Plan. Bonn 13-14.1.
More informationBioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland
Bioabsorbable Scaffolding: Technology and Clinical Update PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland Disclosures I am not Ron Waksman 1 Clinical experience with AMS
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationCyclosporine absorption profiles in pediatric kidney and liver transplant patients
Pediatr Nephrol (2003) 18:1275 1279 DOI 10.1007/s00467-003-1260-8 ORIGINAL ARTICLE J. M. Kovarik Peter F. Hoyer Robert Ettenger Jeffrey Punch Marianne Soergel Cyclosporine absorption profiles in pediatric
More informationIntervention: How and to which extent is technology helping us?
Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationPUBLISHED VERSION. Originally published at: PERMISSIONS
PUBLISHED VERSION Steven J. Chadban, Josette Marie Eris, John Kanellis, Helen Pilmore, Po Chang Lee, Soo Kun Lim, Chad Woodcock, Nicol Kurstjens, Graeme Russ A randomized, controlled trial of everolimus-based
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationCoronary Plaque Sealing: The DEFER Study and more...
Coronary Plaque Sealing: The DEFER Study and more... How Waiting Can Be Beneficial in Stable Coronary Artery Disease Patients ESC, Stockholm, 2005 M. Romanens, 21.09.2005 at www.kardiolab.ch DEFER Study:
More informationFAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS
Coronary Physiology In The Cathlab FAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS Educational Training Program ESC European Heart House april 7th 9th 2011 Nico H.J.Pijls, MD, PhD Catharina Hospital,
More informationWound Healing Complications with De Novo Sirolimus Versus Mycophenolate Mofetil-Based Regimen in Cardiac Transplant Recipients
American Journal of Transplantation 2006; 6: 986 992 Blackwell Munksgaard C 2006 The Authors Journal compilation C 2006 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationThe addition of anti-cd25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients GUIDELINES SEARCH STRATEGY
nep_2.fm Page 5 Friday, January 26, 200 6:46 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology120-558 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 20012S1584MiscellaneousCalcineurin
More informationReview Article The Role of mtor Inhibitors in Liver Transplantation: Reviewing the Evidence
Hindawi Publishing Corporation Journal of Transplantation Volume 2014, Article ID 845438, 45 pages http://dx.doi.org/10.1155/2014/845438 Review Article The Role of mtor Inhibitors in Liver Transplantation:
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationThe Case for Intravenous EDTA Chelation Therapy, August, 2006 update.
The Case for Intravenous EDTA Chelation Therapy, August, 2006 update. Positive Dr. Johanna Mendez (Columbia, S.A.) and Dr. Martin Dayton discussing contents of a chelation treatment in a clinical setting
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationJournal of the American College of Cardiology Vol. 45, No. 11, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 11, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.02.069
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationSirolimus versus Calcineurin Inhibitor-based Immunosuppressive Therapy in Kidney Transplantation A 4-year Follow-up
Transplantation Sirolimus versus Calcineurin Inhibitor-based Immunosuppressive Therapy in Kidney Transplantation A 4-year Follow-up Mohsen Nafar, 1 Behrang Alipour, 2 Pedram Ahmadpoor, 1 Fatemeh Pour-Reza-Gholi,
More informationBasic Science in Transplantation. Greg Hirsch Atlantic Transplant Centre Dalhousie/CDHA
Basic Science in Transplantation Greg Hirsch Atlantic Transplant Centre Dalhousie/CDHA Objectives Review Transplant Vasculopathy Summarize relevant work from our group from the past ten years concerning
More informationSpotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound
Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Department of Cardiovascular Medicine Heart and Vascular Institute
More informationGlucose Intolerance, as Reflected by Hemoglobin A 1c Level, Is Associated With the Incidence and Severity of Transplant Coronary Artery Disease
Journal of the American College of Cardiology Vol. 43, No. 6, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.08.063
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
More informationRENAL ARTERY STENOSIS. Grand Rounds 10/11/2011
RENAL ARTERY STENOSIS Grand Rounds 10/11/2011 ARAS Prevalence- 0.5% overall population, 5.5% in ckd pts No correlation between ischemic nephropathy and severity of stenosis Increased risk of vascular events-
More informationCURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961
CURRICULUM VITAE July 5, 2014 Name Chang-Kwon Oh Date of Birth August 15, 1961 Present Academic & Hospital Appointment Professor, Department of Surgery Ajou University, School of Medicine Chief, Department
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (1999) 14: 394 399 Original Article Nephrology Dialysis Transplantation Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil Rudolf P.
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationPharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents
BUMC Proceedings 1999;12:110-112 Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationMalmö Diet and Cancer Study incl. CV-cohort. Cardiovascular Endpoints
The Malmö Diet and Cancer Study Department of Clinical Sciences Skåne University Hospital, Malmö Lund University Malmö Diet and Cancer Study incl. CV-cohort Cardiovascular Endpoints End of follow-up: 31
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationJournal of the American College of Cardiology Vol. 39, No. 6, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 6, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01714-X
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 09 Mar 2019 16:29:06 GMT) CTRI Number CTRI/2010/091/000679 [Registered on: 23/08/2010] - Last Modified On 10/07/2015 Post Graduate Thesis Type of Trial
More informationAdvances of immunosuppressive therapy for heart transplantation
Advances of immunosuppressive therapy for heart transplantation Katherine Lietz Department of Cardiology, Division of Advanced Heart Failure and Heart Transplantation, University of Minnesota, Minneapolis,
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More information